Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02323906
Title Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Age Groups: adult
Covered Countries USA

No variant requirements are available.